Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Possible Link between Lantus and Cancer Requires Further Study: EASD
July 13, 2009
- TPA Provides Generics Comparison List Online
July 13, 2009
- Clarify Causes of Gender, Ethnic Differences in Lung Cancer: Dr Kawaguchi
July 13, 2009
- Eiken Licenses LAMP Method to Toshiba
July 13, 2009
- Drug Cost Ratio Remains Virtually Flat at 29.0% in FY2008
July 13, 2009
- Research-Driven Firms Should Not Rely on Off-Patent Products: Mr Kinoshita
July 13, 2009
- TOPICS 2 articles
July 13, 2009
- Korosho to Create Prevention-Oriented Medical Safety System: Mr Mori
July 13, 2009
- Quintiles Leads Int'l Clinical Trials in Asia
July 13, 2009
- REGULATORY NEWS IN BRIEF
July 13, 2009
- Eisai Gives Up Filing Application for Pediatric Indication for Aricept
July 13, 2009
- Astellas to Fill Shortfall in Late-Stage Development with Licensing
July 13, 2009
- Eisai Launches New R&D Organization
July 13, 2009
- GSK Drops SGLT2 Inhibitor Licensed from Kissei
July 13, 2009
- Chugai Obtains 51% Share in Market for Antibody Pharmaceuticals in Japan
July 13, 2009
- Wyeth Enters into Comprehensive Agreement with NHO for Clinical Trials
July 13, 2009
- Nippon Kayaku: Generics Drive Sales Up to ¥45.77 Bil.
July 13, 2009
- i3 to Embark on CRO Market in Japan in Earnest
July 13, 2009
- ON THE MOVE
July 13, 2009
- Selection of Patients Holds Key to Success of Molecular-Targeted Drugs
July 13, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…